New, popular injectable weight loss drugs — GLP-1 drugs — are ... up from $125 million in 2022. Already in 2022, GLP-1 drugs accounted for 5 percent of pharmacy spending among people with ...

Drugs such as Novo ... by up to 50% according to a new study, adding to mounting evidence that the drugs yield health benefits beyond diabetes and weight loss. In a study published Thursday ...

The new weight-loss drugs have created “a hope and optimism ... by at least 5 percent in most participants after 56 weeks. A 2022 trial of 201 teens aged 12 to 18 reported a higher treatment ...

But now, a new study in The New England Journal of Medicine shows that they may want to consider a self-injection option – of the weight loss drug semaglutide. People with moderate ...

As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim their waistlines, a new report finds.

Blockbuster diabetes and weight loss drugs, known as GLP-1 treatments, could help people struggling with alcohol and opioid addiction, according to a new study published Thursday in the scientific ...

Oct 30 (Reuters) - The lowest dose of Novo Nordisk's (NOVOb.CO), opens new tab weight-loss drug ... on the U.S. Food and Drug Administration's shortage list since early 2022.

This is a national health crisis. When it was discovered that new diabetes drugs induced rapid and substantial weight loss, it received quite a bit of attention from a population at such risk for ...